

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: Entheon Biomedical Corp. (“the “Issuer”).

Trading Symbol: ENBI

Number of Outstanding Listed Securities: 40,766,648

Date: November, 2020

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On November 5, the Issuer announced that it had completed the previously announced business combination with Entheon Holdings Corp. (formerly, Entheon Biomedical Corp.) and had received final approval to list the Resulting Issuer Shares on the Canadian Securities Exchange (“CSE”) pursuant to the amalgamation agreement dated June 30, 2020, as amended, among the Issuer, Entheon Holdings Corp. and 1254912 B.C. Ltd. (the “Transaction”).

In addition, the Issuer consolidated its issued and outstanding common shares (the “Consolidation”) on the basis of one post-Consolidation common share for every three (3) pre-Consolidation common shares of the Issuer.

On November 12, the Issuer announced that it had commenced trading on the CSE under the symbol “ENBI”.

On November 26, the Issuer announced that its shares had commenced trading on the Frankfurt Stock Exchange under the symbol “1XU1”.

2. Provide a general overview and discussion of the activities of management.

Management has been focused on developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

As described in Section, 2 the Issuer, subject to all requisite regulatory approvals and permits, intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

This section is not applicable to the Issuer.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

This section is not applicable to the Issuer.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

This section is not applicable to the Issuer.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

As described in Section 1, the arm's length acquisition of all issued and outstanding shares of Entheon Holdings Corp. by way of a three-cornered amalgamation on the basis of one common share for each common share of Entheon Holdings Corp. purchased.

8. Describe the acquisition of new customers or loss of customers.

This section is not applicable to the Issuer.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

This section is not applicable to the Issuer.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

This section is not applicable to the Issuer.

11. Report on any labour disputes and resolutions of those disputes if applicable.

This section is not applicable to the Issuer.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

This section is not applicable to the Issuer.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

This section is not applicable to the Issuer.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
----------	---------------	---------------------	--------------------------------

Common Shares	29,845,805	(2)	N/A
Units	4,117,886	(3)	\$1,544,207.25 to be used towards general working capital
Units	100,000	(4)	N/A
Warrants	211,297	(5)	N/A
Common Shares	289,997	(6)	\$89,400 to be used towards general working capital

(1) State aggregate proceeds and intended allocation of proceeds.

(2) Pursuant to the Transaction described in Section 1. 3,050,001 shares are subject to escrow.

(3) Pursuant to a private placement of subscription receipts in 1254912 B.C. Ltd. ("Subco"), a wholly-owned subsidiary of the Issuer, the Issuer issued units upon the closing to the Transaction. Each unit was purchased at \$0.375 and consists of one common share and one-half of one warrant, exercisable into an additional common share at \$0.60 for a period of 2 years.

(4) Pursuant to the Subco private placement, the Issuer issued finder's units. Each finder's unit consists of one common share and one-half of one warrant, exercisable into an additional common share at \$0.60 for a period of 2 years.

(5) Pursuant to the Subco private placement, the Issuer issued finder's warrants. Each finder's warrant is exercisable into one common share at \$0.375 for a period of 2 years.

(6) Pursuant to exercise of stock options at prices between \$0.10 to \$0.12 per share.

15. Provide details of any loans to or by Related Persons.

This section is not applicable to the Issuer.

16. Provide details of any changes in directors, officers or committee members.

On November 5, Guy Charette, Marc-Andre Lavoie, Jean Rainville and Jean Francoise Perras resigned as directors and officers.

Timothy Ko, Andrew Hegle, Christopher Gondi and Ruth Chun were appointed to the Board of Directors.

The Audit Committee changed to Timothy Ko, Ruth Chun and Christopher Gondi.

In addition, Timothy Ko was appointed President and CEO, Brandon Schwabe as CFO, Kelly Pladson as Corporate Secretary and Andrew Hegle as Chief Science Officer.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

This section is not applicable to the Issuer.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: December 4, 2020

Brandon Schwabe
Name of Director or Senior Officer

"Brandon Schwabe"
Signature

CFO
Official Capacity

Issuer Details Name of Issuer Entheon Biomedical Corp.	For Month End November	Date of Report YY/MM/D 20/12/04
Issuer Address 211-3030 Lincoln Avenue		
City/Province/Postal Code Coquitlam, BC, V3B 6B4	Issuer Fax No. n/a	Issuer Telephone No. (604) 562-3932
Contact Name Timothy Ko	Contact Position CEO	Contact Telephone No. (604) 562-3932
Contact Email Address: timothy@entheonbiomedical.com	Web Site Address https://entheonbiomedical.com	